International Exhibits Solutions to Simplify the Customer Experience at ACT Expo 2025
ANAHEIM, Calif., April 23, 2025 /PRNewswire/ — International Motors, LLC * ('International') will showcase its digitally enabled solutions dedicated to the customer experience at ACT Expo 2025 in Anaheim, California April 28 – May 1.
'At International, we're investing in innovative solutions to create an exceptional customer experience,' said Debbie Shust, vice president, Customer Insights & Experience, International. 'It's not just about delivering vehicles—it's about delivering confidence. In a dynamic environment, we simplify the journey, support long-term success, and show up as a true partner every step of the way.'
Fleet Decarbonization
International offers end-to-end consulting services to support customers in reaching their fleet decarbonization goals. These services include electric readiness assessments, infrastructure planning, grant support, and onboarding assistance. Customers can begin their journey by visiting their local International® dealer to tailor a decarbonization strategy that is best suited for their business.
With more than 10 million real-world miles, International's battery-electric vehicles have been meeting customer demands in practical scenarios, assisting customers in their decarbonization journeys.
With the announcement of the International® eRH™ Series, an all-electric Class 8 regional haul tractor, the company expands its electric vehicle lineup to meet demands of the heavy-duty market. The eRH joins the International eMV™ Series and the IC Bus™ Electric CE Series in the International electric vehicle lineup.
Recognizing that fleet decarbonization happens at different paces for customers, International also provides advanced diesel solutions For example, the LT with the S13 Integrated Powertrain delivers at least 5% more in fuel economy than any competitor in the on-highway aero category.** The S13 Integrated is also certified for use with R100 renewable diesel.
Electric Maintenance Solutions
International provides planned maintenance service contracts to ensure that customers' operating, maintenance, and service needs are met and supported by our expansive dealer network. These contracts ensure that battery-electric trucks and buses are seamlessly integrated and maintained through proactive service planning.
This white-glove experience is tailored to enhance uptime via scheduled maintenance intervals, solutions like proactive parts planning, advanced technician scheduling, and a new digital ecosystem designed to predict service and maintenance needs aimed at driving efficiency across International® and IC Bus® dealerships.
The new digital ecosystem provides greater visibility into fleets' health-based vehicle data allowing customers and dealers to schedule planned maintenance appointments three to four weeks ahead of time. During this already planned downtime, fleets and dealers can also proactively identify other needed repairs and campaigns.
International Service Contracts include planned maintenance and can also include powertrain coverage, chassis coverage, and optional towing coverage. International Service Contracts are available for either five or six years on every new battery-electric truck. Electric bus terms for service contracts vary.
International Financial Payment Program for Bundled Solutions
Beyond financing for traditional diesel trucks, International® Financial is also a partner for electric-powered trucks and chargers. This partnership extends past the hardware needed to operate in the battery-electric vehicle ecosystem with a Payment Program that enables customers to access International Service Contracts seamlessly. Importantly, the Payment Program allows our customers to opt for planned maintenance over the term of the contract, with no associated financing cost.
The Payment Program for International Service Contracts is available for electric vehicles whether or not the vehicle is financed through International Financial. Visit the International Financial EV page for more information.
International is dedicated to providing innovative solutions that propel our customers forward. By minimizing downtime and enhancing operational efficiency, we ensure our customers can spend their time and attention focusing on continuous growth and success of their core business. To learn more about these customer solutions, visit the International booth (#5640) at ACT Expo April 28 – May 1 at the Anaheim Convention Center or explore International.com.
ABOUT INTERNATIONAL
Based in Lisle, Illinois, International Motors, LLC* creates solutions that deliver greater uptime and productivity to our customers throughout the full operation of our commercial vehicles. We build International® trucks and engines and IC Bus® school and commercial buses that are as tough and as smart as the people who drive them. We also develop Fleetrite® aftermarket parts. In everything we do, our vision is to accelerate the impact of sustainable mobility to create the cleaner, safer world we all deserve. As of 2021, we joined Scania, MAN and Volkswagen Truck & Bus in TRATON GROUP, a global champion of the truck and transport services industry. To learn more, visit www.International.com.
*International Motors, LLC is d/b/a International Motors USA LLC in Illinois and Ohio.
**The International® LT® with S13® Integrated Powertrain was tested head-to-head using TMC Type IV testing methodology against competitive on-highway aero models with comparable specifications: Freightliner Cascadia DD15, Kenworth T60 MX13, Volvo VNL D13. Testing proved the International LT with S13 Integrated Powertrain to be at least 5% more fuel efficient than these models.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
23 minutes ago
- Malaysian Reserve
Shiji Releases 2025 Hospitality Distribution Technology Chart: Navigating a Rapidly Evolving Ecosystem
Consolidation, AI, social media booking, and direct channel growth define the next era of hotel distribution. BARCELONA, Spain, June 11, 2025 /PRNewswire/ — Shiji, the global hospitality technology innovator, today announced the launch of its 2025/2026 Hospitality Distribution Technology Chart, offering the industry's most up-to-date visual guide to the ever-changing world of hotel distribution. Now in its tenth year, the annual chart has become a trusted reference for hoteliers, investors, and tech providers seeking clarity in a crowded and complex technology landscape. The 2025/2026 edition captures a year defined by market consolidation, social media's rise as a direct booking channel, and a new wave of AI-powered, API-friendly solutions. A Snapshot of the New Distribution Reality From new players to evolving categories, the chart reflects key shifts in how hospitality companies connect with travelers across channels. The 2025 update introduces three new sections: Marketplace, Social Media with Booking, and Upselling. These additions highlight the growing influence of non-traditional booking paths and revenue opportunities. Meanwhile, a surge in brand evolutions and strategic acquisitions continues to reshape competitive dynamics. Key Trends Identified in the 2025/2026 Chart Include: The emergence of Marketplace platforms as important distribution avenues. Social media evolving from an inspiration tool to a booking engine. Upselling solutions becoming central to revenue strategy. AI integration across nearly every category of hotel technology. A shift toward end-to-end platforms delivering unified experiences. Growing emphasis on direct booking performance and ownership. Demand for open APIs and interoperable systems as hotels seek flexibility. The Rise of Social and Alternative Booking Paths For the first time, platforms like Douyin (TikTok China) and WeChat appear on the chart in a new 'Social Media with booking' category, acknowledging the growing role of social commerce in travel decisions. Likewise, the 'Marketplace' section spotlights new platforms giving hotels more distribution options outside traditional OTAs. Technology that Drives Revenue and Flexibility Hotels continue to invest in tech that delivers clear ROI, whether through smarter upselling, better direct booking performance, or enhanced business analytics tools. Open APIs and flexible integrations are no longer just nice to have; they are mission critical. An Industry Compass 'The hotel distribution landscape is evolving faster than ever,' said Natalie Kimball, Vice President of Strategic Accounts for Americas and EMEA at Shiji Horizon Distribution. 'Our 2025/2026 chart helps hoteliers make sense of that evolution by tracking not just the companies involved, but the trends shaping their decisions.' The Shiji Hospitality Distribution Technology Chart was first launched in 2015 and is curated with input from independent experts and hospitality stakeholders worldwide. It is freely available for download and widely used by hotel brands, consultants, and media. To download the full 2025/2026 chart and accompanying industry analysis, click here: Hotel Distribution Technology Chart 2025/2026 About Shiji Shiji is a multi-national technology company that provides software solutions and services for enterprise companies in the hospitality, food service, retail, and entertainment industries, ranging from hospitality technology platforms, hotel property management solutions, food and beverage and retail systems, payment gateways, data management, online distribution, and more. Founded in 1998 as a network solutions provider for hotels, Shiji today comprises over 5,000 employees in 80+ subsidiaries and brands in over 31 countries, serving more than 91,000 hotels, 200,000 restaurants, and 600,000 retail outlets. For more information, visit Media Contact:Gabriella Alverio AlborsMarketing Manager, AmericasShiji (404) 948 – 4001
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Kelley Blue Book, Experian Team Up to Bring Buyers Better Vehicle History Reports
Unmatched Trust and Transparency from Detailed Reports to Boost Buyer Confidence and Drive More Conversions ATLANTA and COSTA MESA, Calif., June 10, 2025 /PRNewswire/ — As the market heats up, along with the competition, it has never been more important to make smart car buying choices based on trusted research. As part of its commitment to drive stronger results for our clients, Kelley Blue Book and Autotrader, Cox Automotive brands, today announced they are expanding their strategic relationship with Experian, a global data and technology company, to co-brand its AutoCheck® vehicle history reports on and vehicle listings. Experian's AutoCheck vehicle history reports offered by Kelley Blue Book combine the power of the storied and trusted Kelley Blue Book brand with the detailed insights Experian already delivers to car buyers and sellers for more efficient decision-making. Experian's AutoCheck vehicle history reports will be available on all eligible listings on both Kelley Blue Book and Autotrader, allowing dealerships to provide potential buyers with detailed vehicle history information and inherent trust in their product. Featured on the vehicle history reports, the proprietary AutoCheck Score offers a quick, clear snapshot of a vehicle's predicted reliability, helping buyers and sellers feel confident every step of the way. 'With proprietary auction data and backed by Kelley Blue Book, the No. 1 trusted automotive brand for shoppers planning to buy in the next six months, dealerships can gain the edge they need to better buy and sell inventory,' said Jessica Stafford, senior vice president, consumer solutions, at Cox Automotive. 'Our clients and consumers will have detailed information to make informed car-buying decisions which, given the current market, is more important than ever before. Increased transparency leads to more confident and informed shopper decisions, and ultimately, more leads for dealers.' Dealerships also benefit from more engagement in listings, reporting with an extensive database of automotive records, and easy-to-understand insights to better compare a vehicle to other similar models currently on the market. In fact, free Experian vehicle history reports drive 44% more lead conversions on Autotrader vehicle detail pages than the leading competitor. * 'Researching and comparing vehicle listings is a critical step in the used car buying experience. Nearly every in-market shopper scours every ounce of information available to help them choose the right vehicle,' said Robert Granados, president of Experian Automotive. 'By joining forces with Kelley Blue Book, we're able to put information about a vehicle's history directly into the hands of more consumers. Now, in-market shoppers will have more transparency when buying a vehicle and feel more confident in their choice.' For more information about Experian AutoCheck offered by Kelley Blue Book, contact your Kelley Blue Book or Autotrader sales representative. *Based on internal analysis of vehicle history report leads submitted from Autotrader listings/VDPs from Dec 2024 – May 2025. Individual results may vary. About Kelley Blue Book Founded in 1926, Kelley Blue Book, The Trusted Resource®, is the vehicle valuation and information source trusted and relied upon by both consumers and the automotive industry for nearly a century. As the industry standard for generations, Kelley Blue Book provides transparent, objective information and data-driven, innovative tools for consumers, automotive dealers and manufacturers. Kelley Blue Book publishes millions of market-reflective values weekly on its top-rated website from its famous Blue Book® Trade-In Values to the Kelley Blue Book® Price Advisor tool, which offers a range for what consumers reasonably can expect to pay for a vehicle in their area. editors rate and review hundreds of new vehicles each year to help consumers understand the Best Cars and Best SUVs to meet their needs. Kelley Blue BookSM Instant Cash Offer provides a redeemable trade-in offer to transaction-ready consumers and conveniently connects them to local participating dealers. Kelley Blue Book's Service Advisor provides guidance on how much to pay for service and repairs, allowing consumers to schedule service with local dealers on Kelley Blue Book also provides vehicle values to finance and insurance companies as well as governmental agencies. Kelley Blue Book is a Cox Automotive brand. About Cox AutomotiveCox Automotive is the world's largest automotive services and technology provider. Fueled by the largest breadth of first-party data fed by 2.3 billion online interactions a year, Cox Automotive tailors leading solutions for car shoppers, auto manufacturers, dealers, lenders and fleets. The company has 29,000+ employees on five continents and a portfolio of industry-leading brands that include Autotrader®, Kelley Blue Book®, Manheim®, vAuto®, Dealertrack®, NextGear Capital™, CentralDispatch® and FleetNet America®. Cox Automotive is a subsidiary of Cox Enterprises Inc., a privately owned, Atlanta-based company with $23 billion in annual revenue. Visit or connect via @CoxAutomotive on X, CoxAutoInc on Facebook or Cox-Automotive-Inc on LinkedIn. About ExperianExperian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money. We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments. We invest in talented people and new advanced technologies to unlock the power of data and to innovate. A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 23,300 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, 'This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible.' [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@
